Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2H7E

Solution structure of the talin F3 domain in complex with a chimeric beta3 integrin-PIP kinase peptide- minimized average structure

Summary for 2H7E
Entry DOI10.2210/pdb2h7e/pdb
Related2H7D
NMR InformationBMRB: 7150
DescriptorTalin-1, Chimera of 24-mer peptide from Integrin beta-3 and 10-mer peptide from Phosphatidylinositol-4-phosphate 5-kinase type-1 gamma (2 entities in total)
Functional Keywordsprotein-peptide complex, alpha helix, beta sheet, structural protein
Biological sourceGallus gallus (chicken)
More
Cellular locationCell projection, ruffle membrane; Peripheral membrane protein; Cytoplasmic side: P54939
Endomembrane system: O70161
Total number of polymer chains2
Total formula weight15755.15
Authors
Wegener, K.L. (deposition date: 2006-06-02, release date: 2007-01-30, Last modification date: 2024-11-06)
Primary citationWegener, K.L.,Partridge, A.W.,Han, J.,Pickford, A.R.,Liddington, R.C.,Ginsberg, M.H.,Campbell, I.D.
Structural basis of integrin activation by talin
CELL(CAMBRIDGE,MASS.), 128:171-182, 2007
Cited by
PubMed Abstract: Regulation of integrin affinity (activation) is essential for metazoan development and for many pathological processes. Binding of the talin phosphotyrosine-binding (PTB) domain to integrin beta subunit cytoplasmic domains (tails) causes activation, whereas numerous other PTB-domain-containing proteins bind integrins without activating them. Here we define the structure of a complex between talin and the membrane-proximal integrin beta3 cytoplasmic domain and identify specific contacts between talin and the integrin tail required for activation. We used structure-based mutagenesis to engineer talin and beta3 variants that interact with comparable affinity to the wild-type proteins but inhibit integrin activation by competing with endogenous talin. These results reveal the structural basis of talin's unique ability to activate integrins, identify an interaction that could aid in the design of therapeutics to block integrin activation, and enable engineering of cells with defects in the activation of multiple classes of integrins.
PubMed: 17218263
DOI: 10.1016/j.cell.2006.10.048
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon